OM
IGMS

Opaleye Management’s IGM Biosciences IGMS Stock Holding History

Opaleye Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-261,000
Closed -$2.18M – 49
2023
Q3 		$2.18M Buy
261,000
+197,500
+311% +$1.68M 0.71% 32
2023
Q2 		$586K Buy
+63,500
New +$711K 0.14% 45

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Opaleye Management's IGMS Position: Q4 2023 in Review

Opaleye Management sold out of IGM Biosciences (IGMS) in Q4 2023, closing a stake of 261,000 shares — an estimated $2.18M sold.

Opaleye Management first reported a position in IGMS in Q2 2023 and held it in 2 quarters. The position peaked at $2.18M in Q3 2023. 72 funds tracked by Wall St. Rank hold IGMS as of Q4 2023.

  • Opaleye Management reported no remaining IGM Biosciences position as of Q4 2023 after selling out during the quarter.
  • Opaleye Management sold 261,000 IGM Biosciences shares in Q4 2023, an estimated $2.18M.
  • Opaleye Management first reported a position in IGM Biosciences in Q2 2023 and held it in 2 quarters.
  • Opaleye Management's IGM Biosciences position peaked at $2.18M in Q3 2023.
  • 72 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2023.

Based on Opaleye Management's 13F filing for Q4 2023, filed 14 Feb 2024.